DR. REDDY'S LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,643 INR | -2.20% |
|
+0.91% | +14.58% |
Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows:
- sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines;
- sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services;
- other (4.4%): sales of generic biopharmaceutical products, development of molecular agents, etc.
Net sales are distributed geographically as follows: India (18.8%), the United States (45%), Russia (9.9%) and other (26.3%).
Sector
Pharmaceuticals
Calendar
2024-07-26
- Q1 2025 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
36
Last Close Price
6,643
INR
Average target price
6,164
INR
Spread / Average Target
-7.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.58% | 13.24B | |
| +56.86% | 848B | |
| +31.64% | 627B | |
| +0.10% | 363B | |
| +15.27% | 318B | |
| +12.44% | 299B | |
| +15.51% | 243B | |
| +16.72% | 225B | |
| +16.46% | 179B | |
| +3.30% | 167B |
- Stock Market
- Equities
- DRREDDY Stock
- News Dr. Reddy's Laboratories Limited
- Dr Reddy Laboratories : Barclays Upgrades Dr. Reddy's Laboratories to Overweight From Equal-Weight, Adjusts Price Target to $70 From $56
